![\"\"](\"https:\/\/www.sinergia2020.polimi.it\/wp-content\/uploads\/2019\/09\/unibas.png\")
<\/p>\n[et_pb_section fb_built=”1″ _builder_version=”3.27.4″ fb_built=”1″ _i=”0″ _address=”0″][et_pb_row _builder_version=”3.27.4″ _i=”0″ _address=”0.0″][et_pb_column type=”4_4″ _builder_version=”3.27.4″ _i=”0″ _address=”0.0.0″][et_pb_text _builder_version=”3.27.4″ _i=”0″ _address=”0.0.0.0″]<\/p>\n
<\/p>\n
<\/p>\n
<\/p>\n
<\/span><\/p>\n ESR1<\/strong><\/p>\n Project Title<\/span>: Developing a miniaturized ex vivo culture system for drug testing on patient-specific tumour specimens.<\/p>\n Objectives<\/span>: The ESR will be trained in the handling and culture of primary cancer tissue using standard cell culture techniques and perfusion-based bioreactor systems. The experience and knowledge will be applied for the development of a mesoscale perfusion-based multi-well devices to allow drug testing on patient-specific tumour tissue. In particular, the ESR will work within a team of engineers, biologists and clinicians to translate our bioreactor experience in a new device suitable for multi-well drug testing that will allow the maintenance of the primary tumour microenvironment in vitro, specifically supporting tumour cells and non-malignant lymphoid cells. In detail, by maintaining both immune and tumour cells, the device will allow to study their interaction and behaviour under therapeutic antibody treatment.<\/p>\n The patient-specific multi-well perfusion-based bioreactor will i) guarantee the ex-vivo culture of primary tumour tissue with preserved microenvironment, while ii) allowing medium-throughput drug screening capabilities. The ESR will adopt engineering design tools (CAD, FEM), state-of-the-art 3D printing techniques and will deal with human sample collection and primary cell culture.<\/p>\n Expected Results<\/span>: A perfusion-based multi-well bioreactor will be designed to allow the ex-vivo preservation of the cellular composition of freshly resected tumour tissue specimens. After a period of validation and qualification, the device will be used in collaboration with oncologists to define patient-specific response to drugs.<\/p>\n Host<\/span>: UNIBAS<\/strong><\/p>\n Main Supervisors<\/span>: Ivan Martin, Manuele Muraro<\/p>\n Duration<\/span>: 36 months<\/p>\n Planned Secondment<\/span>: BIOMIMX (3 months) to learn soft lithography technique and to acquire new knowledge regarding in vitro models design and validation requirement during the first year; LIFETEC (2 months) to receive training on the culture and maintenance of tissue biopsies ex-vivo during the second year; ST-UK (1 month) in the last year to accomplish a commercialization training.<\/p>\n Enrolment in Doctoral Degree<\/span>: PhD in Biomedical Engineering (Faculty of Medicine) at the University of Basel<\/strong><\/p>\n
\n